Mustang Bio (MBIO)
Develops a combined oncolytic-virus and CAR T treatment for recurrent brain tumors.
MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks
VANCOUVER, British Columbia, June 09, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company commercializing AI-driven voice analytics for intoxication and fatigue detection, is pleased to announce the Company has completed the manufacture of and delivered its first prototype Edge AI Intoxication Detection Kiosks. The first prototypes are a hardware and software solution designed for office and industrial use to detect intoxication and fatigue and improve safety in the workplace.
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
MindBio Announces Closing of Private Placement
Vancouver, British Columbia – April 1, 2026 – TheNewswire - MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF) (the “ Company ” or “ MindBio ”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce that it has closed its previously announced upsized non-brokered private placement (the “ Offering ”) for gross proceeds of $1,437,828.87
MindBio Announces Upsize to Private Placement up to $1.5 Million
Vancouver, British Columbia – TheNewswire - March 19, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “ Company ” or “ MindBio ”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection announces today that it is upsizing its non-brokered private placement (the “ Offering ”) previously announced on February 18, 2026 from $650,000 to up to $1,500,000, pursuant to which the Company intends to now issue up to 2,500,000 units of the Company (the “ Units ”) at a price of $0.60 per Unit for gross proceeds of up to $1,500,000. Each Unit will consist of one common share of the Company (each, a “ Share ”) and one Share purchase warrant (each, a “ Warrant ”). Each Warrant will entitle the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days.
Critical Contrast: Mustang Bio (NASDAQ:MBIO) & AstraZeneca (NASDAQ:AZN)
Mustang Bio (NASDAQ: MBIO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of current recommendations
MindBio Announces Private Placement to Raise up to $650,000
Vancouver, British Columbia - TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “ Company ” or “ MindBio ”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce it will conduct a non-brokered private placement (the “ Offering ”) to raise gross proceeds of up to $650,000 to accelerate the development of its enterprise intoxication detection solution, including the production of proprietary hardware and edge technologies for remote deployment in the mining industry.
MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform
Vancouver, British Columbia – TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6) (OTCQB: MBQIF) (“MindBio” or the “Company”) , a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection, today announced it has commenced development of a proprietary edge computing platform, including dedicated hardware, to enable large-scale deployment in the mining industry. The Company is working with an experienced engineering firm with expertise in hardware and sensor development to design and manufacture the Company's integrated Edge AI solution for real-time, on-device voice analysis in remote and infrastructure-limited environments. Prototype development is nearing completion, with hardware manufacturing and field-ready deployment expected in Q2 2026.
CSE Bulletin: Consolidation - MindBio Therapeutics Corp. (MBIO)
Toronto, Ontario--(Newsfile Corp. - Le 4 novembre/November 2025) - MindBio Therapeutics Corp. has announced
Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company has received assay results from underground face sampling of lateral development from the 1105 level at the Mustang Mine. Lateral development is mining conducted along the vein to allow for equipment access required for later stope extraction between levels. This development is conducted at approximately 3 X 3 metre dimensions, larger than the 1.8 metre width of the actual mining stopes. The 1105 level is located 1,105 metres above mean sea level and represents one of the upper most levels of the Mustang Mine. Sampling on this level was conducted to support future stopes identified on the Alhambra, BK and BK9870 veins. Sampling is conducted by cutting a linear horizontal channel approximately 10 centimeters wide across the width of the development face.
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation (“AbbVie”), for $1.0 million.
Mustang Bio Announces Closing of $8 Million Public Offering
WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering, for the issuance and sale of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Series C-2 warrants to purchase up to 2,657,807 shares of common stock, at a combined public offering price of $3.01 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The warrants have an exercise price of $3.01 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series C-1 warrants will expire five years from the date of stockholder approval and the Series C-2 warrants will expire twenty-four months from the date of stockholder approval.
Mustang Bio Announces Pricing of $8 Million Public Offering
WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Series C-2 warrants to purchase up to 2,657,807 shares of common stock, at a combined public offering price of $3.01 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $3.01 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series C-1 warrants will expire five years from the date of stockholder approval and the Series C-2 warrants will expire twenty-four months from the date of stockholder approval. The closing of the offering is expected to occur on or about February 7, 2025, subject to the satisfaction of customary closing conditions.
Mustang Bio Announces Reverse Stock Split
WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. Mustang expects its common stock to begin trading on a split-adjusted basis on The Nasdaq Stock Market as of the commencement of trading on January 16, 2025.
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 16,877,638 shares of its common stock having an exercise price of $0.237 per share, originally issued in May 2024. The issuance or resale of the shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-278006). The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $4 million, prior to deducting placement agent fees and offering expenses payable by the Company.
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
Why are Mustang Bio shares (MBIO) up almost 500%?
The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day.
Why Is Mustang Bio (MBIO) Stock Up 347% Today?
Mustang Bio (NASDAQ: MBIO ) stock is taking off on Monday after the clinical-stage biopharmaceutical company announced positive results from a study. The recent news includes favorable results from the company's Phase 1.2 clinical trial of MB-106.